 SAN DIEGO, CA, July 29, 2021 GLOBE NEWSWIRE -- via NewMediaWire -- Sigyn Therapeutics, Inc. OTC Markets: SIGY, a medical technology company focused on the treatment of life-threatening inflammatory conditions, today announced the completion of a pilot animal study that validated the feasibility of a clinical protocol that resulted in the safe administration of Sigyn TherapyTM during six-hour treatment exposures. The pilot study represents the first-in-mammal use of Sigyn Therapy in a clinical setting. 